A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and determining their health care-associated transmission, researchers found.

The local gene-sequencing company and a U.S. clothing company face sales restrictions in China as part of that country’s ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Genomic sequencing specialist Illumina (NASDAQ: ILMN) was something of a victim in the U.S.-China trade spat on Tuesday.

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results , but sales were flat year on year at $1.1 billion. On the ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...